Pharmacometric Reviews Increasingly Influence FDA Regulatory Decisions
This article was originally published in Pharmaceutical Approvals Monthly
Drug makers should routinely perform exposure-response analyses across Phase II and III studies to find consistencies across trials, FDA said in a recent survey of 31 NDAs submitted between 2005 and 2006.
You may also be interested in...
Using anonymous examples at the recent AACR meeting, FDA’s Tatiana Prowell highlights mistakes made and lessons learned in oncology drug reviews.
FDA holds the key to making model-based drug development and drug-disease model libraries successful, speakers at a Jan. 24-25 Drug Industry Association meeting concluded
The debate over analysis of clinical trial endpoints in FDA review documents for Pfizer’s Chantix (varenicline) provides a window into how the agency’s view of smoking cessation trial design is changing as new therapeutic classes emerge.